Standardizing terms for clinical pharmacogenetic test results: Consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

Genetics in Medicine

Volumn 19, Issue 2, 2017, Pages 215-223

  Caudle, Kelly E ^a   Dunnenberger, Henry M ^b   Freimuth, Robert R ^c   Peterson, Josh F ^d   Burlison, Jonathan D ^a   Whirl Carrillo, Michelle ^e   Scott, Stuart A ^f   Rehm, Heidi L ^g   Williams, Marc S ^h   Klein, Teri E ^e   Relling, Mary V ^a   Hoffman, James M ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c MAYO CLINIC   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; CONSENSUS; DECISION SUPPORT SYSTEM; DELPHI STUDY; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; NOMENCLATURE; PHARMACOGENETICS; PHENOTYPE; SCIENTIST; ELECTRONIC HEALTH RECORD; QUESTIONNAIRE; STANDARDS;

ALLELES; ELECTRONIC HEALTH RECORDS; GENETIC TESTING; HUMANS; PHARMACOGENETICS; PHENOTYPE; SURVEYS AND QUESTIONNAIRES; TERMINOLOGY AS TOPIC;

EID: 85011846544     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.87     Document Type: Article

References (40)

1. Payne TH, Corley S, Cullen TA, et al. Report of the AMIA EHR-2020 Task Force on the status and future direction of EHRs. J Am Med Inform Assoc 2015;22: 1102-1110.
2. Wei WQ, Leibson CL, Ransom JE, et al. Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus. J Am Med Inform Assoc 2012;19:219-224.
3. Relling M V, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526: 343-350.
4. Richards S, Aziz N, Bale S, et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424.
5. Rehm HL, Berg JS, Brooks LD, et al.; ClinGen. ClinGen-the Clinical Genome Resource. N Engl J Med 2015;372:2235-2242.
6. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014;15:209-217.
7. Shirts BH, Salama JS, Aronson SJ, et al. CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record. J Am Med Inform Assoc 2015;22:1231-1242.
8. Dalkey N, Helmer O. An experimental application of the Delphi method to the use of experts. Manag Sci 1963;9:458-467.
9. Beretta R. A critical review of the Delphi technique. Nurse Res 1996;3:79-89.
10. Green B, Jones M, Hughes D, Williams A. Applying the Delphi technique in a study of GPs' information requirements. Health Soc Care Community 1999;7:198-205.
11. von der Gracht HA. Consensus measurement in Delphi studies Review and implications for future quality assurance. Technol Forecast Soc Change 2012;79:125-1536.
12. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs 2000;32:1008-1015.
13. Kalman LV, Agúndez J, Appell ML, et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharmacol Ther 2016;99:172-185.
14. Hsu CC, Sandford BA. The Delphi technique: making sense of consensus. Practical Assess Res Eval 2007;12:1-8.
15. Sumsion T. The Delphi technique: an adaptive research tool. Br J Occupat Ther 1998;61:153-156.
16. Gammal RS, Court MH, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther 2016;99:363-369.
17. Hicks JK, Bishop JR, Sangkuhl K, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015;98:127-134.
18. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther 2015;98:19-24.
19. Martin MA, Hoffman JM, Freimuth RR, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update. Clin Pharmacol Ther 2014;95:499-500.
20. National Center for Biotechnology Information. ClinVar. Clinical significance on ClinVar aggregate records. http://www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/#clinsig-agg. Accessed 14 April 2016.
21. Johnson JA, Gong L, Whirl-Carrillo M, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-629.
22. Flockhart DA, O'Kane D, Williams MS, et al.; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-150.
23. Tsuchiya KD, Shaffer LG, Aradhya S, et al. Variability in interpreting and reporting copy number changes detected by array-based technology in clinical laboratories. Genet Med 2009;11:866-873.
24. Wiley LK, Tarczy-Hornoch P, Denny JC, et al. Harnessing next-generation informatics for personalizing medicine: a report from AMIA's 2014 Health Policy Invitational Meeting. J Am Med Inform Assoc 2016;23:413-419.
25. HL7 V2 Implementation Guide: Clinical Genomics; Fully LOINC-Qualified Genetic Variation Model, Release 2; 2013.
26. McDonald CJ, Huff SM, Suico JG, et al. LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem 2003;49:624-633.
27. Huff SM, Rocha RA, McDonald CJ, et al. Development of the Logical Observation Identifier Names and Codes (LOINC) vocabulary. J Am Med Inform Assoc 1998;5:276-292.
28. Deckard J, McDonald CJ, Vreeman DJ. Supporting interoperability of genetic data with LOINC. J Am Med Inform Assoc 2015;22:621-627.
29. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 2014;21(e1):e93-e99.
30. Goldspiel BR, Flegel WA, DiPatrizio G, et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. JAMIA. 2014;21:522-528.
31. Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42(Database issue):D980-D985.
32. Okoli C, Pawlowski S. The Delphi method as a research tool: an example, design considerations and applications. Information and Management 2004;42: 15-29.
33. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012;91:450-458.
34. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet 2012;82:388-394.
35. Overby CL, Erwin AL, Abul-Husn NS, et al. Physician attitudes toward adopting genome-guided prescribing through clinical decision support. J Pers Med 2014;4:35-49.
36. Peterson J F, Field JR, Shi Y, et al. Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J 2015; e-pub ahead of print 11 August 2015.
37. Hicks JK, Crews KR, Hoffman JM, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther 2012;92:563-566.
38. Peterson J F, Bowton E, Field JR, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med 2013;15:833-841.
39. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014;166C:45-55.
40. Caudle KE, Rettie AE, Whirl-Carrillo M, et al.; Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther 2014;96:542-548.